Article Versions Notes

Kong D, Mai Z, Chen Y, Luo L, Liu H, Zhao L, Huang R, Wang S, Chen R, Zhou H, et al. ATL I, Acts as a SIRT6 Activator to Alleviate Hepatic Steatosis in Mice via Suppression of NLRP3 Inflammasome Formation. Pharmaceuticals. 2022; 15(12):1526. https://doi.org/10.3390/ph15121526

Kong, Danli, Zhenhua Mai, Yongze Chen, Ling Luo, Hao Liu, Le Zhao, Ruixian Huang, Shuang Wang, Rong Chen, Hao Zhou, and et al. 2022. "ATL I, Acts as a SIRT6 Activator to Alleviate Hepatic Steatosis in Mice via Suppression of NLRP3 Inflammasome Formation" Pharmaceuticals 15, no. 12: 1526. https://doi.org/10.3390/ph15121526

Kong, D., Mai, Z., Chen, Y., Luo, L., Liu, H., Zhao, L., Huang, R., Wang, S., Chen, R., Zhou, H., Chen, H., Zhang, J., Yu, H., & Ding, Y. (2022). ATL I, Acts as a SIRT6 Activator to Alleviate Hepatic Steatosis in Mice via Suppression of NLRP3 Inflammasome Formation. Pharmaceuticals, 15(12), 1526. https://doi.org/10.3390/ph15121526